Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Singapore Institute of Advanced Medicine Holdings Ltd. has forged a strategic partnership with Australian biopharmaceutical firm EnGeneIC to propel cancer treatment advancements in Asia, focusing on delivering personalized, targeted therapies with minimal toxicity. Through exclusive distribution in 17 Asian countries and global rights for EDV-based theranostics, the collaboration aims to enhance Singapore’s position as a premier medical tourism destination. The alliance is set to develop and distribute cutting-edge anti-cancer technologies, including a state-of-the-art nanocell drug platform.
For further insights into SG:9G2 stock, check out TipRanks’ Stock Analysis page.